MNI BRIEF: Fed's Bowman Expects Continued Economic Strength

MNI: FED'S BOWMAN: WATCHING LABOR MARKET CLOSELY

MNI BRIEF: Real Interest Rates Have Risen - ECB's Escriva

MNI China Daily Summary: Friday, September 27

MNI: PBOC Net Drains CNY238.9 Bln via OMO Friday; Rate Cut

MNI: PBOC Sets Yuan Parity Lower At 7.0101 Fri; +4.14% Y/Y

MNI: UNIV OF MICHIGAN CONSUMER SENTIMENT FINAL SEP INDEX 70.1

EZ/UK Bond Supply Calendar: BoE APF on Monday

MNI: US AUG PERSONAL INCOME +0.2%; NOM PCE +0.2%

CANADA: Politics Week: Parliament Opens With Early Election Threats

AUSTRALIA: Albanese Lines Up Budget for May Election

AUSTRALIA: Albanese Lines Up Budget for May Election

© 1982-2024 MNI. All rights reserved.
Terms | Privacy
Log Out
Free Trial

HEALTHCARE: Sanofi (SANFP: A1 pos / AA): Consumer Unit Sale Imminent

HEALTHCARE
BulletCredit Bullets
  • Bloomberg are reporting that banks and private credit have lined up €10bn in financing for a takeover of the Consumer Health unit
  • The total price tag was said to be $20bn back in June
  • Sanofi may keep a significant minority stake to use as liquidity in the future
  • Sanofi needs to use the proceeds to replace its pipeline given that Dupixent is 28% of sales
  • No immediate credit impact for Sanofi
  • Consumer Unit is 11% of sales
72 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.
  • Bloomberg are reporting that banks and private credit have lined up €10bn in financing for a takeover of the Consumer Health unit
  • The total price tag was said to be $20bn back in June
  • Sanofi may keep a significant minority stake to use as liquidity in the future
  • Sanofi needs to use the proceeds to replace its pipeline given that Dupixent is 28% of sales
  • No immediate credit impact for Sanofi
  • Consumer Unit is 11% of sales